RESUMEN
Earlier clinical trials demonstrated the anti-hypertensive effect of amlodipine, a new calcium channel blocker of the dihydropyridine type. In the present comparative study, we investigated the anti-hypertensive effect of amlodipine in comparison with a combination of nifedipine and mefruside. In both groups, the anti-hypertensive effect was comparable. Normalization of the supine diastolic blood pressure was observed in 72.3% of patients treated with amlodipine and in 66.6% of those patients in the combination group. Both drugs were generally well tolerated, with a somewhat higher incidence of side effects being observed in the combination group. The study shows that amlodipine monotherapy in mild-to-moderate hypertension is equally as effective as combination therapy with nifedipine/mefruside, with amlodipine being superior in terms of tolerability.
Asunto(s)
Bloqueadores de los Canales de Calcio/uso terapéutico , Hipertensión/tratamiento farmacológico , Mefrusida/uso terapéutico , Nifedipino/análogos & derivados , Nifedipino/uso terapéutico , Adulto , Anciano , Amlodipino , Combinación de Medicamentos , Femenino , Humanos , Masculino , Mefrusida/administración & dosificación , Persona de Mediana Edad , Nifedipino/administración & dosificaciónAsunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Dolor de Espalda/tratamiento farmacológico , Neuritis del Plexo Braquial/tratamiento farmacológico , Fenilpropionatos/uso terapéutico , Tiazinas/uso terapéutico , Antiinflamatorios no Esteroideos/efectos adversos , Método Doble Ciego , Evaluación de Medicamentos , Medicina Familiar y Comunitaria , Humanos , PiroxicamRESUMEN
A double-blind study was carried out in two parallel groups of patients with mild to moderate hypertension to assess the efficacy and tolerance of the combination 20 mg penbutolol plus 3 mg piretanide in comparison to 40 mg penbutolol alone over a period of 6 weeks. Active drug treatment in the 51 patients studied was preceded by a 2-week period of placebo. The results showed that in both groups there was an effective reduction in systolic and diastolic blood pressure compared with initial levels. Although there was no significant difference between the groups, the normalization of diastolic blood pressure (less than 95 mmHg) was achieved in 70% of the patients receiving the combination and in 59% of the patients treated with penbutolol alone. Pulse rate decreased in both groups, body weight only in the combination group. The biochemical and haematological parameters showed no clinically relevant changes during treatment with either drug regimens. Minor side-effects definitely or probably associated with the treatment were observed in both groups but were generally mild and did not interfere with treatment. No patient withdrew prematurely from the trial.
Asunto(s)
Hipertensión/tratamiento farmacológico , Penbutolol/uso terapéutico , Propanolaminas/uso terapéutico , Sulfonamidas/uso terapéutico , Adulto , Anciano , Presión Sanguínea/efectos de los fármacos , Ensayos Clínicos como Asunto , Método Doble Ciego , Quimioterapia Combinada , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Penbutolol/administración & dosificación , Penbutolol/efectos adversos , Distribución Aleatoria , Sulfonamidas/administración & dosificación , Sulfonamidas/efectos adversos , Factores de TiempoRESUMEN
The efficacy and tolerability of penbutolol alone and in combination with piretanide at two dose levels were investigated in a double-blind parallel group study in patients with mild to moderate essential hypertension. All three treatments were given as a single daily dose. One hundred and eight patients entered the study; 82 completed a 7-day placebo run-in period followed by 3 weeks of active therapy. Penbutolol 20 mg plus piretanide 3 mg and penbutolol 40 mg plus piretanide 6 mg both produced a significantly greater reduction in supine diastolic blood pressure (16% and 19% respectively) than penbutolol 20 mg (9%). The reduction in supine diastolic blood pressure was significant for all three treatments with respects to the baseline reading. Side-effects were generally mild and transient and were similar in type and incidence in the three groups. Six patients did not complete the trial period because of an excessive response to the hypotensive medication: five in the high dose combination group, and one in the low dose combination group. Low doses of penbutolol (20 mg) and piretanide (3 mg) used in combination and in a once-daily administration provide a simple, effective and well tolerated regimen for patients with mild to moderate hypertension.